MedPath

Samus Therapeutics, Inc.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.samustherapeutics.com

A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN

Phase 2
Withdrawn
Conditions
Accelerated Phase MPN
Blast Phase MPN
Interventions
First Posted Date
2022-11-10
Last Posted Date
2022-11-10
Lead Sponsor
Samus Therapeutics, Inc.
Registration Number
NCT05612633

Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma

Phase 1
Terminated
Conditions
Recurrent Glioblastoma Multiforme (GBM)
Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma
Grade 3 or 4 Astrocytoma
Glioblastoma Surgery
Interventions
First Posted Date
2021-03-04
Last Posted Date
2022-11-17
Lead Sponsor
Samus Therapeutics, Inc.
Target Recruit Count
7
Registration Number
NCT04782609
Locations
🇺🇸

University of California, Las Angeles Medical Center, Los Angeles, California, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis

Phase 2
Withdrawn
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Drug: Placebo
First Posted Date
2020-08-10
Last Posted Date
2022-11-17
Lead Sponsor
Samus Therapeutics, Inc.
Registration Number
NCT04505358

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

Phase 2
Terminated
Conditions
Alzheimer Disease
Interventions
Radiation: Tau Positron emission tomography (PET)
Radiation: Fluorodeoxyglucose (FDG) Positron emission tomography (PET)
Diagnostic Test: Cerebrospinal fluid (CSF) Biomarkers
Diagnostic Test: Blood Biomarkers
Behavioral: Rating Scales
Drug: Placebo
First Posted Date
2020-03-17
Last Posted Date
2022-11-17
Lead Sponsor
Samus Therapeutics, Inc.
Target Recruit Count
4
Registration Number
NCT04311515
Locations
🇺🇸

JEM Research, Lake Worth, Florida, United States

🇺🇸

Advanced Clinical Institute, Inc., Neptune, New Jersey, United States

🇺🇸

Brain Matters Research, Delray Beach, Florida, United States

and more 7 locations

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Phase 1
Terminated
Conditions
Post-Polycythemia Vera Myelofibrosis (Post-PV MF)
Primary Myelofibrosis (PMF)
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
First Posted Date
2019-05-02
Last Posted Date
2022-11-17
Lead Sponsor
Samus Therapeutics, Inc.
Target Recruit Count
11
Registration Number
NCT03935555
Locations
🇺🇸

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Marin Cancer Care - Greenbrae (California Cancer Care A Medical Group, Inc. - Greenbrae), Larkspur, California, United States

🇺🇸

MD Anderson, Houston, Texas, United States

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

Phase 1
Terminated
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2019-05-02
Last Posted Date
2023-04-18
Lead Sponsor
Samus Therapeutics, Inc.
Target Recruit Count
40
Registration Number
NCT03935568
Locations
🇺🇸

ICON Early Phase Services, San Antonio, Texas, United States

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Phase 1
Terminated
Conditions
Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Myelofibrosis
Interventions
First Posted Date
2017-12-14
Last Posted Date
2022-11-15
Lead Sponsor
Samus Therapeutics, Inc.
Target Recruit Count
4
Registration Number
NCT03373877
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

🇺🇸

Ochsner Clinic Foundation, New Orleans, Louisiana, United States

and more 7 locations

PET Imaging of Subjects Using 124I-PU-AD

Early Phase 1
Terminated
Conditions
Lymphoma
Solid Malignancy
Alzheimer Disease
Myeloma
Interventions
Device: PET Scan
Other: Blood Draws
First Posted Date
2017-12-13
Last Posted Date
2023-04-18
Lead Sponsor
Samus Therapeutics, Inc.
Target Recruit Count
5
Registration Number
NCT03371420
Locations
🇺🇸

Memorial Sloan Kettering, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath